Gene Variant Databases
Leveraging expert-curated knowledge from COSMIC and QIAGEN to avoid pitfalls, qualify candidate drug targets, and accelerate early discovery
263 views
In this talk, our experts discuss how biopharmaceutical companies can leverage key genomic, biomedical, and clinical trial databases to improve and accelerate cancer drug discovery while avoiding potential pitfalls. Through a series of use cases, attendees will learn about expert-curated knowledge from the Wellcome Sanger Institute and QIAGEN, and how to use these resources to better predict cancer-driving effects of mutations, identify available drugs that target specific variants, and accelerate indication expansion and repurposing of existing cancer therapies.
Learning objectives:
Examine use-cases of how to leverage expert-curated databases across multiple phases of cancer drug development.
Discover key applications of these databases, including determining the function, frequency, and actionability of specific mutations.
Discuss potential pitfalls and clinical consequences, and how to avoid them early with data-driven drug target and biomarker qualification.
Related videos
Gene Variant Databases
Access to real-world data and 2 decades of expert curation
Across oncology applications, from research to molecular testing and...
Gene Variant Databases
Identify meaningful mutations in somatic tumor testing
From Information Overload to Actionable Insights Precision medicine is...
Gene Variant Databases
Precisely target the causes of malignancy on a molecular level
Key to precision oncology is the development of expert databases that...
Gene Variant Databases
How to simplify somatic NGS analysis & reduce literature review time by 90% with HSMD
Across clinical oncology applications, from molecular testing to cancer...